Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa

Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically

Ferraro, M. J. (2000) · Cited by 16,875 · see citing works

ACETYLORNITHINASE OF ESCHERICHIA COLI: PARTIAL PURIFICATION AND SOME PROPERTIES

Vogel, H. J., & Bonner, D. M. (1956) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)65874-0 · Cited by 4,001 · see citing works

Metallo-β-Lactamases: the Quiet before the Storm?

Walsh, T. R., Toleman, M. A., Poirel, L., & Nordmann, P. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.2.306-325.2005 · Cited by 1,430 · see citing works

Comprehensive transposon mutant library of Pseudomonas aeruginosa

Jacobs, M. A., Alwood, A., Thaipisuttikul, I., Spencer, D. H., Haugen, E., Ernst, S., Will, O., Kaul, R., Raymond, C. K., Levy, R., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2036282100 · Cited by 1,129 · see citing works

Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance

Woodford, N., Turton, J. F., & Livermore, D. M. (2011) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2011.00268.x · Cited by 881 · see citing works

Pseudomonas aeruginosa – a phenomenon of bacterial resistance

Strateva, T., & Yordanov, D. (2009) · Journal of Medical Microbiology · doi:10.1099/jmm.0.009142-0 · Cited by 803 · see citing works

Mechanisms of Multidrug Resistance in Acinetobacter Species and Pseudomonas aeruginosa

Bonomo, R. A., & Szabó, D. (2006) · Clinical Infectious Diseases · doi:10.1086/504477 · Cited by 739 · see citing works

Current Epidemiology and Growing Resistance of Gram-Negative Pathogens

Livermore, D. M. (2012) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2012.27.2.128 · Cited by 425 · see citing works

“Stormy waters ahead”: global emergence of carbapenemases

Patel, G., & Bonomo, R. A. (2013) · Frontiers in Microbiology · doi:10.3389/fmicb.2013.00048 · Cited by 423 · see citing works

Of Pseudomonas, porins, pumps and carbapenems

Livermore, D. M. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/47.3.247 · Cited by 393 · see citing works

Siderophores as drug delivery agents: application of the “Trojan Horse” strategy

Möllmann, U., Heinisch, L., Bauernfeind, A., Köhler, T., & Ankel‐Fuchs, D. (2009) · BioMetals · doi:10.1007/s10534-009-9219-2 · Cited by 275 · see citing works

In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains

Kohira, N., West, J. M., Ito, A., Ito-Horiyama, T., Nakamura, R., Sato, T., Rittenhouse, S. F., Tsuji, M., & Yamano, Y. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01695-15 · Cited by 247 · see citing works

In Vitro Properties of BAL30072, a Novel Siderophore Sulfactam with Activity against Multiresistant Gram-Negative Bacilli

Page, M. G. P., Dantier, C., & Desarbre, E. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01525-09 · Cited by 227 · see citing works

Iron uptake regulation in Pseudomonas aeruginosa

Cornélis, P., Matthijs, S., & Oeffelen, L. V. (2009) · BioMetals · doi:10.1007/s10534-008-9193-0 · Cited by 218 · see citing works

Transition Metals in Microbial Metabolism

Winkelmann, G., & Carrano, C. J. (2022) · CRC Press eBooks · doi:10.1201/9781003211129 · Cited by 197 · see citing works

In vitroantimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria

Ito, A., Kohira, N., Bouchillon, S. K., West, J. M., Rittenhouse, S. F., Sader, H. S., Rhomberg, P. R., Jones, R. N., Yoshizawa, H., Nakamura, R., et al. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv402 · Cited by 188 · see citing works

Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases

Ito-Horiyama, T., Ishii, Y., Ito, A., Sato, T., Nakamura, R., Fukuhara, N., Tsuji, M., Yamano, Y., Yamaguchi, K., & Tateda, K. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03098-15 · Cited by 188 · see citing works

Emergence of NDM-1 Metallo-β-Lactamase in Pseudomonas aeruginosa Clinical Isolates from Serbia

Jovčić, B., Lepšanović, Z., Šuljagić, V., Rackov, G., Begović, J., Topisirović, L., & Kojić, M. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00226-11 · Cited by 183 · see citing works

The concept of iron bioavailability and its assessment

Wienk, K. J. H., Marx, J. J. M., & Beynen, A. C. (1999) · European Journal of Nutrition · doi:10.1007/s003940050046 · Cited by 179 · see citing works

Iron-regulated outer membrane proteins of Escherichia coli K-12 and mechanism of action of catechol-substituted cephalosporins

Curtis, N. A. C., Eisenstadt, R. L., East, S. J., Cornford, R. J., Walker, L., & White, A. J. (1988) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.32.12.1879 · Cited by 137 · see citing works

Adaptation-Based Resistance to Siderophore-Conjugated Antibacterial Agents by Pseudomonas aeruginosa

Tomaras, A. P., Crandon, J. L., McPherson, C. J., Banevicius, M. A., Finegan, S. M., Irvine, R. L., Brown, M. F., O'Donnell, J. P., & Nicolau, D. P. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00629-13 · Cited by 110 · see citing works

Metallo beta lactamases inPseudomonas aeruginosaand Acinetobacter species

Gupta, V. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.2.131 · Cited by 96 · see citing works

Clinically Relevant Gram-Negative Resistance Mechanisms Have No Effect on the Efficacy of MC-1, a Novel Siderophore-Conjugated Monocarbam

McPherson, C. J., Aschenbrenner, L. M., Lacey, B. M., Fahnoe, K. C., Lemmon, M. M., Finegan, S. M., Tadakamalla, B., O'Donnell, J. P., Mueller, J. P., & Tomaras, A. P. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01345-12 · Cited by 91 · see citing works

Targeting iron assimilation to develop new antibacterials

Foley, T. L., & Simeonov, A. M. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.708335 · Cited by 82 · see citing works

Pharmacodynamic Profiling of a Siderophore-Conjugated Monocarbam in Pseudomonas aeruginosa: Assessing the Risk for Resistance and Attenuated Efficacy

Kim, A., Kutschke, A., Ehmann, D. E., Patey, S. A., Crandon, J. L., Gorseth, E., Miller, A. A., McLaughlin, R. E., Blinn, C. M., Chen, A., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00831-15 · Cited by 77 · see citing works

Role of outer membrane protein OprD and penicillin-binding proteins in resistance of Pseudomonas aeruginosa to imipenem and meropenem

Farra, A., Islam, S., Strålfors, A., Sörberg, M., & Wretlind, B. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.12.016 · Cited by 70 · see citing works

Involvement of Fe Uptake Systems and AmpC β-Lactamase in Susceptibility to the Siderophore Monosulfactam BAL30072 in Pseudomonas aeruginosa

van Delden, C., Page, M. G. P., & Köhler, T. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02474-12 · Cited by 54 · see citing works

Extrusion of Penem Antibiotics by Multicomponent Efflux Systems MexAB-OprM, MexCD-OprJ, and MexXY-OprM of Pseudomonas aeruginosa

Okamoto, K., Gotoh, N., & Nishino, T. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2696-2699.2002 · Cited by 54 · see citing works

A highly sensitive, simple determination of serum iron using chromazurol B

Garčic, A. (1979) · Clinica Chimica Acta · doi:10.1016/0009-8981(79)90003-2 · Cited by 35 · see citing works

Potentiation of Antibacterial Activity of the MB-1 Siderophore-Monobactam Conjugate Using an Efflux Pump Inhibitor

Tomaras, A. P., Crandon, J. L., McPherson, C. J., & Nicolau, D. P. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04172-14 · Cited by 32 · see citing works

In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011

Kanj, S. S., Whitelaw, A. C., & Dowzicky, M. J. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.10.011 · Cited by 28 · see citing works

Uptake of BRL 41897A, a C(7) α-formamido substituted cephalosporin, via the ferri-pyochelin transport system of Pseudomonas aeruginosa

Gensberg, K., Doyle, E. J., Perry, D. A., & Smith, A. W. (1994) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/34.5.697 · Cited by 12 · see citing works

Antimicrobial susceptibility among Gram-positive and Gram-negative isolates collected in Europe between 2004 and 2010

Denis, O., Nonhoff, C., & Dowzicky, M. J. (2014) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2014.05.001 · Cited by 8 · see citing works

Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections

Doi, Y. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz830 · Cited by 661 · see citing works

New Antibiotics for Multidrug-Resistant Bacterial Strains: Latest Research Developments and Future Perspectives

Terreni, M., Taccani, M., & Pregnolato, M. (2021) · Molecules · doi:10.3390/molecules26092671 · Cited by 623 · see citing works

Developing new antimicrobial therapies: Are synergistic combinations of plant extracts/compounds with conventional antibiotics the solution?

Cock, I. E., Cheesman, M. J., Ilanko, A., & Blonk, B. (2017) · Pharmacognosy Reviews/Bioinformatics Trends/Pharmacognosy review · doi:10.4103/phrev.phrev_21_17 · Cited by 564 · see citing works

Infections Caused by Carbapenem-Resistant Enterobacteriaceae: An Update on Therapeutic Options

Sheu, C., Chang, Y.-T., Lin, S., Chen, Y., & Hsueh, P. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00080 · Cited by 534 · see citing works

Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli

Zhanel, G. G., Golden, A. R., Zelenitsky, S., Wiebe, K., Lawrence, C. K., Adam, H. J., Idowu, T., Domalaon, R., Schweizer, F., Zhanel, M. A., et al. (2019) · Drugs · doi:10.1007/s40265-019-1055-2 · Cited by 446 · see citing works

Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial

Portsmouth, S., van Veenhuyzen, D., Echols, R., Machida, M., Ferreira, J. C. A., Ariyasu, M., Tenke, P., & Nagata, T. D. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30554-1 · Cited by 420 · see citing works

In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria

Ito, A., Sato, T., Oota, M., Takemura, M., Nishikawa, T., Toba, S., Kohira, N., Miyagawa, S., Ishibashi, N., Matsumoto, S., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01454-17 · Cited by 411 · see citing works

Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin

Sato, T., & Yamawaki, K. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz826 · Cited by 390 · see citing works

Critical analysis of antibacterial agents in clinical development

Theuretzbacher, U., Bush, K., Harbarth, S., Paul, M., Rex, J. H., Tacconelli, E., & Thwaites, G. E. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-020-0340-0 · Cited by 381 · see citing works

Treatment of Infections Due to MDR Gram-Negative Bacteria

Bassetti, M., Peghin, M., Vena, A., & Giacobbe, D. R. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00074 · Cited by 335 · see citing works

Metallo-β-lactamases in the Age of Multidrug Resistance: From Structure and Mechanism to Evolution, Dissemination, and Inhibitor Design

Bahr, G., González, L. J., & Vila, A. J. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00138 · Cited by 284 · see citing works

Antibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?

Domalaon, R., Idowu, T., Zhanel, G. G., & Schweizer, F. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00077-17 · Cited by 283 · see citing works

Pseudomonas aeruginosa: Infections, Animal Modeling, and Therapeutics

Wood, S. J., Kuzel, T. M., & Shafikhani, S. H. (2023) · Cells · doi:10.3390/cells12010199 · Cited by 267 · see citing works

The Role of Iron and Siderophores in Infection, and the Development of Siderophore Antibiotics

Page, M. G. P. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz825 · Cited by 250 · see citing works

In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016

Hackel, M., Tsuji, M., Yamano, Y., ECHOLS, R. M., Karlowsky, J. A., & Sahm, D. F. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01968-17 · Cited by 237 · see citing works

An update on β-lactamase inhibitor discovery and development

Docquier, J., & Mangani, S. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.11.002 · Cited by 221 · see citing works

Thiazoles, Their Benzofused Systems, and Thiazolidinone Derivatives: Versatile and Promising Tools to Combat Antibiotic Resistance

Cascioferro, S., Parrino, B., Carbone, D., Schillaci, D., Giovannetti, E., Cirrincione, G., & Diana, P. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01245 · Cited by 205 · see citing works

In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study)

Hackel, M., Tsuji, M., Yamano, Y., ECHOLS, R. M., Karlowsky, J. A., & Sahm, D. F. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00093-17 · Cited by 200 · see citing works

In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study)

Kazmierczak, K. M., Tsuji, M., Wise, M. G. G., Hackel, M., Yamano, Y., ECHOLS, R. M., & Sahm, D. F. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.10.007 · Cited by 197 · see citing works

Cefiderocol: A Novel Agent for the Management of Multidrug-Resistant Gram-Negative Organisms

Wu, J. Y., Srinivas, P., & Pogue, J. M. (2020) · Infectious Diseases and Therapy · doi:10.1007/s40121-020-00286-6 · Cited by 195 · see citing works

In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria

Yamano, Y. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz827 · Cited by 193 · see citing works

Bifunctional antimicrobial conjugates and hybrid antimicrobials

Klahn, P., & Brönstrup, M. (2017) · Natural Product Reports · doi:10.1039/c7np00006e · Cited by 182 · see citing works

Acinetobacter baumannii can use multiple siderophores for iron acquisition, but only acinetobactin is required for virulence

Sheldon, J. R., & Skaar, E. P. (2020) · PLOS Pathogens · doi:10.1371/journal.ppat.1008995 · Cited by 177 · see citing works

Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship

Aoki, T., Yoshizawa, H., Yamawaki, K., Yokoo, K., Sato, J., Hisakawa, S., Hasegawa, Y., Kusano, H., Sano, M., Sugimoto, H., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.06.014 · Cited by 175 · see citing works

New Perspectives on Antimicrobial Agents: Cefiderocol

McCreary, E. K., Heil, E. L., & Tamma, P. D. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02171-20 · Cited by 174 · see citing works

Thinking Outside the Box—Novel Antibacterials To Tackle the Resistance Crisis

Lakemeyer, M., Zhao, W., Mandl, F. A. M., Hammann, P., & Sieber, S. A. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201804971 · Cited by 170 · see citing works

Treatment Options for Colistin Resistant Klebsiella pneumoniae: Present and Future

Petrosillo, N., Taglietti, F., & Granata, G. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8070934 · Cited by 165 · see citing works

Cefiderocol Antimicrobial Susceptibility Testing Considerations: the Achilles' Heel of the Trojan Horse?

Simner, P. J., & Patel, R. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.00951-20 · Cited by 164 · see citing works

Siderophore–Antibiotic Conjugate Design: New Drugs for Bad Bugs?

Negash, K. H., Norris, J. K. S., & Hodgkinson, J. T. (2019) · Molecules · doi:10.3390/molecules24183314 · Cited by 154 · see citing works

A Synthetic Dual Drug Sideromycin Induces Gram-Negative Bacteria To Commit Suicide with a Gram-Positive Antibiotic

Liu, R., Miller, P. A., Vakulenko, S. B., Stewart, N. K., Boggess, B., & Miller, M. J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00218 · Cited by 153 · see citing works

Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens

Dobias, J., Tendon, V. D., Poirel, L., & Nordmann, P. (2017) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-017-3063-z · Cited by 151 · see citing works

Iron Acquisition Systems of Gram-negative Bacterial Pathogens Define TonB-Dependent Pathways to Novel Antibiotics

Klebba, P. E., Newton, S. M. C., Six, D. A., Kumar, A., Yang, T., Nairn, B. L., Munger, C., & Chakravorty, S. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01005 · Cited by 150 · see citing works

In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015

Karlowsky, J. A., Hackel, M., Tsuji, M., Yamano, Y., ECHOLS, R. M., & Sahm, D. F. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.11.007 · Cited by 149 · see citing works

The Infectious Diseases Society of America’s 10 × ’20 Initiative (10 New Systemic Antibacterial Agents US Food and Drug Administration Approved by 2020): Is 20 × ’20 a Possibility?

Talbot, G. H., Jezek, A., Murray, B. E., Jones, R. N., Ebright, R. H., Nau, G. J., Rodvold, K. A., Newland, J. G., Boucher, H. W., & The Infectious Diseases Society of America (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz089 · Cited by 147 · see citing works

Cefiderocol Resistance in Acinetobacter baumannii: Roles of β-Lactamases, Siderophore Receptors, and Penicillin Binding Protein 3

Malik, S., Kaminski, M. A., Landman, D., & Quale, J. M. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01221-20 · Cited by 141 · see citing works

Reproducibility of broth microdilution MICs for the novel siderophore cephalosporin, cefiderocol, determined using iron-depleted cation-adjusted Mueller-Hinton broth

Hackel, M., Tsuji, M., Yamano, Y., ECHOLS, R. M., Karlowsky, J. A., & Sahm, D. F. (2019) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2019.03.003 · Cited by 133 · see citing works

TonB-Dependent Receptor Repertoire of Pseudomonas aeruginosa for Uptake of Siderophore-Drug Conjugates

Lüscher, A., Moynié, L., Auguste, P. S., Bumann, D., Mazza, L., Pletzer, D., Naismith, J. H., & Köhler, T. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00097-18 · Cited by 126 · see citing works

Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects

Saisho, Y., Katsube, T., White, S., Fukase, H., & Shimada, J. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02163-17 · Cited by 124 · see citing works

Treatment Options for Carbapenem-Resistant Gram-Negative Infections

Fritzenwanker, M., Imirzalioglu, C., Herold, S., Wagenlehner, F. R. A., Zimmer, K., & Chakraborty, T. (2018) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2018.0345 · Cited by 124 · see citing works

In Vivo Pharmacodynamic Study of Cefiderocol, a Novel Parenteral Siderophore Cephalosporin, in Murine Thigh and Lung Infection Models

Nakamura, R., Ito-Horiyama, T., Takemura, M., Toba, S., Matsumoto, S., Ikehara, T., Tsuji, M., Sato, T., & Yamano, Y. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02031-18 · Cited by 117 · see citing works

Multidrug-Resistant Pseudomonas Infections: Hard to Treat, But Hope on the Horizon?

Nguyen, L., Garcia, J. A., Gruenberg, K., & MacDougall, C. (2018) · Current Infectious Disease Reports · doi:10.1007/s11908-018-0629-6 · Cited by 112 · see citing works

Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections

Syed, Y. Y. (2021) · Drugs · doi:10.1007/s40265-021-01580-4 · Cited by 112 · see citing works

Learning from bacterial competition in the host to develop antimicrobials

Raffatellu, M. (2018) · Nature Medicine · doi:10.1038/s41591-018-0145-0 · Cited by 110 · see citing works

Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia

Delgado-Valverde, M., Conejo, M. C., Serrano, L., Fernández-Cuenca, F., & Pascual, Á. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa117 · Cited by 109 · see citing works

Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014)

Kohira, N., Hackel, M., Ishioka, Y., Kuroiwa, M., Sahm, D. F., Sato, T., Maki, H., & Yamano, Y. (2020) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2020.07.009 · Cited by 109 · see citing works

ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum β-Lactamases and Carbapenemases

Jacobs, M. R., Abdelhamed, A. M., Good, C. E., Rhoads, D. D., Hujer, K. M., Hujer, A. M., Domitrovic, T., Rudin, S. D., Richter, S. S., van Duin, D., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01801-18 · Cited by 108 · see citing works

Cefiderocol, a Siderophore Cephalosporin for Gram‐Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment

Katsube, T., ECHOLS, R. M., Ferreira, J. C. A., Krenz, H., Berg, J. K., & Galloway, C. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.841 · Cited by 106 · see citing works

Total synthesis and antimicrobial evaluation of natural albomycins against clinical pathogens

Lin, Z., Xu, X., Zhao, S. Y., Yang, X., Guo, J. J., Zhang, Q., Jing, C., Chen, S., & He, Y. (2018) · Nature Communications · doi:10.1038/s41467-018-05821-1 · Cited by 105 · see citing works

In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019

Karlowsky, J. A., Hackel, M. A., Takemura, M., Yamano, Y., Echols, R., & Sahm, D. F. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01990-21 · Cited by 104 · see citing works

Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Immunocompetent-Rat Respiratory Tract Infection Models Recreating Human Plasma Pharmacokinetics

Matsumoto, S., Singley, C. M., Hoover, J. L., Nakamura, R., ECHOLS, R. M., Rittenhouse, S. F., Tsuji, M., & Yamano, Y. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00700-17 · Cited by 101 · see citing works

Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection Model

Monogue, M. L., Tsuji, M., Yamano, Y., ECHOLS, R. M., & Nicolau, D. P. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01022-17 · Cited by 101 · see citing works

The Chemical Relationship Among Beta-Lactam Antibiotics and Potential Impacts on Reactivity and Decomposition

Turner, J. M., Muraoka, A., Bedenbaugh, M., Childress, B., Pernot, L., Wiencek, M., & Peterson, Y. K. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.807955 · Cited by 96 · see citing works

Infections by multidrug-resistant Gram-negative Bacteria: What's new in our arsenal and what's in the pipeline?

Koulenti, D., Song, A., Ellingboe, A., Abdul-Aziz, M. H., Harris, P. N. A., Gavey, E., & Lipman, J. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.10.011 · Cited by 95 · see citing works

A Comprehensive Overview of the Antibiotics Approved in the Last Two Decades: Retrospects and Prospects

Shi, Z., Zhang, J., Tian, L., Xin, L., Liang, C., Ren, X., & Li, M. (2023) · Molecules · doi:10.3390/molecules28041762 · Cited by 94 · see citing works

Cefiderocol: A Siderophore Cephalosporin

El-Lababidi, R. M., & Rizk, J. G. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020929988 · Cited by 91 · see citing works

Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections

Parsels, K. A., Mastro, K. A., Steele, J. M., Thomas, S. J., & Kufel, W. D. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab015 · Cited by 90 · see citing works

Cefiderocol: a novel siderophore cephalosporin

Choi, J. J., & McCarthy, M. W. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1426745 · Cited by 88 · see citing works

Emerging therapies against infections with Pseudomonas aeruginosa

Tümmler, B. (2019) · F1000Research · doi:10.12688/f1000research.19509.1 · Cited by 87 · see citing works

Co-regulation of biofilm formation and antimicrobial resistance in Acinetobacter baumannii: from mechanisms to therapeutic strategies

Mendes, S. R. M., Combo, S. I., Allain, T., Domingues, S., Buret, A. G., & Silva, G. (2023) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-023-04677-8 · Cited by 87 · see citing works

Metallo-β-lactamase-mediated antimicrobial resistance and progress in inhibitor discovery

Yang, Y., Yan, Y., Schofield, C. J., McNally, A., Zong, Z., & Li, G. (2023) · Trends in Microbiology · doi:10.1016/j.tim.2023.01.013 · Cited by 83 · see citing works

Defining the Role of Novel β-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms

Tamma, P. D., & Hsu, A. J. (2019) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piz002 · Cited by 82 · see citing works

In vitroactivity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible Gram-negative bacteria from Europe

Longshaw, C. M., Manissero, D., Tsuji, M., ECHOLS, R. M., & Yamano, Y. (2020) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlaa060 · Cited by 78 · see citing works

Stability and low induction propensity of cefiderocol against chromosomal AmpC β-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae

Ito, A., Nishikawa, T., Oota, M., Ito-Horiyama, T., Ishibashi, N., Sato, T., Tsuji, M., & Yamano, Y. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky317 · Cited by 74 · see citing works

Bismuth-based drugs sensitize Pseudomonas aeruginosa to multiple antibiotics by disrupting iron homeostasis

Xia, Y., Wei, X., Gao, P., Wang, C., de Jong, A., Chen, J. H.-K., Rodrí­guez, M. J., Rodríguez‐Nogales, A., Diez‐Echave, P., Gálvez, J., et al. (2024) · Nature Microbiology · doi:10.1038/s41564-024-01807-6 · Cited by 69 · see citing works

New Antibiotics for Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia

Bassetti, M., Mularoni, A., Giacobbe, D. R., Castaldo, N., & Vena, A. (2022) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0041-1740605 · Cited by 67 · see citing works

Polypharmacological drug actions of recently FDA approved antibiotics

Wetzel, C., Lonneman, M., & Wu, C. A. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112931 · Cited by 66 · see citing works

Carbapenem-Resistant Enterobacterales: Considerations for Treatment in the Era of New Antimicrobials and Evolving Enzymology

Lasko, M. J., & Nicolau, D. P. (2020) · Current Infectious Disease Reports · doi:10.1007/s11908-020-0716-3 · Cited by 66 · see citing works

Long-Term Compassionate Use of Cefiderocol To Treat Chronic Osteomyelitis Caused by Extensively Drug-Resistant Pseudomonas aeruginosa and Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae in a Pediatric Patient

Alamarat, Z. I., Babic, J. T., Tran, T. T., Wootton, S. H., Dinh, A. Q., Miller, W. R., Hanson, B., Wanger, A. R., Gary, J. L., Arias, C. A., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01872-19 · Cited by 65 · see citing works

Siderophore natural products as pharmaceutical agents

Swayambhu, G., Bruno, M. J., Gulick, A. M., & Pfeifer, B. A. (2021) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2021.01.021 · Cited by 64 · see citing works

Synthetic sideromycins (skepticism and optimism): selective generation of either broad or narrow spectrum Gram-negative antibiotics

Lin, Y., Ghosh, M., Miller, P. A., Möllmann, U., & Miller, M. J. (2019) · BioMetals · doi:10.1007/s10534-019-00192-6 · Cited by 64 · see citing works

Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence

Viale, P., Sandrock, C. E., Ramírez, P., Rossolini, G. M., & Lodise, T. P. (2023) · Annals of Intensive Care · doi:10.1186/s13613-023-01146-5 · Cited by 63 · see citing works

Cefiderocol: Clinical application and emergence of resistance

Wang, L., Zhu, J., Chen, L., & Du, H. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.101034 · Cited by 63 · see citing works

Sideromycins as Pathogen-Targeted Antibiotics

Wencewicz, T. A., & Miller, M. J. (2017) · Topics in medicinal chemistry · doi:10.1007/7355_2017_19 · Cited by 63 · see citing works

Activity of Cefiderocol Alone and in Combination with Levofloxacin, Minocycline, Polymyxin B, or Trimethoprim-Sulfamethoxazole against Multidrug-Resistant Stenotrophomonas maltophilia

Biagi, M. J., Vialichka, A., Jurkovic, M., Wu, T.-S., Shajee, A., Lee, M., Patel, S., Mendes, R. E., & Wenzler, E. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00559-20 · Cited by 63 · see citing works

Metallo-sideromycin as a dual functional complex for combating antimicrobial resistance

Wang, C., Xia, Y., Wang, R., Li, J., Chan, C.-L., Kao, R. Y. T., Toy, P. H., Ho, P., Li, H., & Sun, H. (2023) · Nature Communications · doi:10.1038/s41467-023-40828-3 · Cited by 61 · see citing works

New antibiotics for Gram-negative pneumonia

Bassetti, M., Magnè, F., Giacobbe, D. R., Bini, L., & Vena, A. (2022) · European Respiratory Review · doi:10.1183/16000617.0119-2022 · Cited by 59 · see citing works

Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae – Identification of LYS228

Reck, F., Bermingham, A., Blais, J., Čápka, V., Cariaga, T. A., Casarez, A. D., Colvin, R. A., Dean, C. R., Fekete, A., Gong, W., et al. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.01.006 · Cited by 59 · see citing works

Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug‐Resistant Gram‐Negative Pathogens

Abdul‐Mutakabbir, J. C., Alosaimy, S., Morrisette, T., Kebriaei, R., & Rybak, M. J. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2476 · Cited by 56 · see citing works

Mechanisms of iron homeostasis in Pseudomonas aeruginosa and emerging therapeutics directed to disrupt this vital process

Sánchez-Jiménez, A., Marcos‐Torres, F. J., & Llamas, M. A. (2023) · Microbial Biotechnology · doi:10.1111/1751-7915.14241 · Cited by 55 · see citing works

Cefiderocol and Sulbactam-Durlobactam against Carbapenem-Resistant Acinetobacter baumannii

Karruli, A., Migliaccio, A., Pournaras, S., Durante‐Mangoni, E., & Zarrilli, R. (2023) · Antibiotics · doi:10.3390/antibiotics12121729 · Cited by 53 · see citing works

Treatment of carbapenem-resistant Pseudomonas aeruginosa infections: a case for cefiderocol

Cantón, R., Doi, Y., & Simner, P. J. (2022) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2022.2071701 · Cited by 53 · see citing works

Design and Syntheses of New Antibiotics Inspired by Nature’s Quest for Iron in an Oxidative Climate

Miller, M. J., & Liu, R. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00004 · Cited by 52 · see citing works

Activity of Cefiderocol Against Enterobacterales , Pseudomonas aeruginosa , and Acinetobacter baumannii Endemic to Medical Centers in New York City

Iregui, A., Khan, Z., Landman, D., & Quale, J. M. (2020) · Microbial Drug Resistance · doi:10.1089/mdr.2019.0298 · Cited by 51 · see citing works

A Serendipitous Mutation Reveals the Severe Virulence Defect of a Klebsiella pneumoniae fepB Mutant

Palacios, M., Broberg, C. A., Walker, K. A., & Miller, V. L. (2017) · mSphere · doi:10.1128/msphere.00341-17 · Cited by 50 · see citing works

Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model

Ghazi, I. M., Monogue, M. L., Tsuji, M., & Nicolau, D. P. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.10.008 · Cited by 50 · see citing works

Siderophores promote cooperative interspecies and intraspecies cross-protection against antibiotics in vitro

Galdino, A. C. M., Vaillancourt, M., Celedonio, D., Huse, K., Doi, Y., Lee, J. S., & Jorth, P. A. (2024) · Nature Microbiology · doi:10.1038/s41564-024-01601-4 · Cited by 49 · see citing works

In vitro resistance development gives insights into molecular resistance mechanisms against cefiderocol

Kriz, R., Spettel, K., Pichler, A., Schefberger, K., Sanz-Codina, M., Lötsch, F., Harrison, N. M., Willinger, B., Zeitlinger, M. A., Burgmann, H., et al. (2024) · The Journal of Antibiotics · doi:10.1038/s41429-024-00762-y · Cited by 49 · see citing works

Innovative perspectives on the discovery of small molecule antibiotics

Cardona, S. T., Rahman, A. S. M. Z., & Nechcoff, J. N. (2025) · npj Antimicrobials and Resistance · doi:10.1038/s44259-025-00089-0 · Cited by 48 · see citing works

Siderophores for medical applications: Imaging, sensors, and therapeutics

Fan, D., & Fang, Q. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120306 · Cited by 48 · see citing works

A Critical Evaluation of Newer β-Lactam Antibiotics for Treatment of Pseudomonas aeruginosa Infections

Blomquist, K. C., & Nix, D. E. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020974003 · Cited by 47 · see citing works

Comparison of Agar Dilution to Broth Microdilution for Testing In Vitro Activity of Cefiderocol against Gram-Negative Bacilli

Albano, M., Karau, M. J., Schuetz, A. N., & Patel, R. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.00966-20 · Cited by 47 · see citing works

Gallium(III)–Salophen as a Dual Inhibitor of Pseudomonas aeruginosa Heme Sensing and Iron Acquisition

Centola, G. A., Deredge, D. J., Hom, K., Ai, Y., Dent, A. T., Xue, F., & Wilks, A. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00138 · Cited by 46 · see citing works

Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety

Lee, Y. R., & Yeo, S. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00955-x · Cited by 46 · see citing works

In Vitro Antibacterial Activity of Cefiderocol against Multidrug-Resistant Acinetobacter baumannii

Abdul‐Mutakabbir, J. C., Nguyen, L., Maassen, P. T., Stamper, K. C., Kebriaei, R., Kaye, K. S., Castanheira, M., & Rybak, M. J. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02646-20 · Cited by 45 · see citing works

In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014–2018 studies in Italy

Stracquadanio, S., Torti, E., Longshaw, C. M., Henriksen, A. S., & Stefani, S. (2021) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2021.04.019 · Cited by 45 · see citing works

Acinetobacter Pneumonia: Improving Outcomes With Early Identification and Appropriate Therapy

Guillamet, C. V., & Kollef, M. H. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy375 · Cited by 44 · see citing works

The Battle Is on: New Beta-Lactams for the Treatment of Multidrug-Resistant Gram-Negative Organisms

Noval, M., Banoub, M. G., Claeys, K. C., & Heil, E. L. (2020) · Current Infectious Disease Reports · doi:10.1007/s11908-020-0710-9 · Cited by 44 · see citing works

Case Report: Successful Rescue Therapy of Extensively Drug-Resistant Acinetobacter baumannii Osteomyelitis With Cefiderocol

Dagher, M. M., Ruffin, F., Marshall, S. H., Taracila, M. A., Bonomo, R. A., Reilly, R. M., Fowler, V. G., & Thaden, J. T. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa150 · Cited by 44 · see citing works

Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol

Bilal, M., Tabei, L. E., Büsker, S., Krauss, C., Fuhr, U., & Taubert, M. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01063-5 · Cited by 43 · see citing works

Siderophore-mediated iron acquisition by <i>Klebsiella pneumoniae</i>

Kumar, A., Chakravorty, S., Yang, T., Russo, T. A., Newton, S. M., & Klebba, P. E. (2024) · Journal of Bacteriology · doi:10.1128/jb.00024-24 · Cited by 42 · see citing works

In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria

Ito, A., Sato, T., Oota, M., Takemura, M., Nishikawa, T., Toba, S., Kohira, N., Miyagawa, S., Ishibashi, N., Matsumoto, S., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01454-17 · Cited by 411 · see citing works

50 Quorum sensing regulation by the nitrogen phosphotransferase system in Pseudomonas aeruginosa

Banerjee, S., Smalley, N. E., Chandler, J. R., Dandekar, A. A., & Cabeen, M. T. (2023) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(23)00985-2

Ferric iron transport system of Pseudomonas aeruginosa PAO1 that functions as the uptake pathway of a novel catechol-substituted cephalosporin, S-9096

Yamano, Y., Nishikawa, T., & Komatsu, Y. (1994) · Applied Microbiology and Biotechnology · doi:10.1007/bf00173995 · Cited by 11 · see citing works

Cefiderocol Antimicrobial Susceptibility Testing Considerations: the Achilles' Heel of the Trojan Horse?

Simner, P. J., & Patel, R. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.00951-20 · Cited by 164 · see citing works

Catecholate siderophore receptor CirA impacts cefiderocol susceptibility in Klebsiella pneumoniae

Lan, P., Lu, Y., Jiang, Y., Wu, X., Yu, Y., & Zhou, J. (2022) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2022.106646 · Cited by 31 · see citing works